PolyPid (PYPD) Total Non-Current Liabilities (2019 - 2026)
PolyPid (PYPD) posted Total Non-Current Liabilities of $3.3 million for Q1 2026, down 7.32% sequentially from $3.6 million in Q4 2025, and down 23.87% YoY from $4.4 million in Q1 2025.
PolyPid (PYPD) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
PolyPid has reported Total Non-Current Liabilities for 8 years, with the latest figure at $3.3 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 23.87% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 23.87% YoY) and the FY2025 annual result came in at $3.6 million, down 25.95% from the prior year.
- Total Non-Current Liabilities eased to $3.3 million in Q1 2026 per PYPD's latest filing, from $3.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $12.8 million in Q1 2023 and troughed at $195000.0 in Q1 2022.
- A 5-year average of $7.3 million and a median of $7.0 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities soared 6459.49% in 2023, then sank 52.32% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $11.6 million in 2022, then fell by 12.14% to $10.2 million in 2023, then tumbled by 52.32% to $4.9 million in 2024, then fell by 25.95% to $3.6 million in 2025, then retreated by 7.32% to $3.3 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $3.3 million, $3.6 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | PolyPid | 113.86 Mn | 107.09 Mn | - | 3.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.24 Mn |
| Mar 31, 2026 | 3.33 Mn |
| Dec 31, 2025 | 3.60 Mn |
| Sep 30, 2025 | 3.85 Mn |
| Jun 30, 2025 | 4.06 Mn |
| Mar 31, 2025 | 4.38 Mn |
| Dec 31, 2024 | 4.86 Mn |
| Sep 30, 2024 | 6.96 Mn |
| Jun 30, 2024 | 7.64 Mn |
| Mar 31, 2024 | 9.06 Mn |
| Dec 31, 2023 | 10.18 Mn |
| Sep 30, 2023 | 11.50 Mn |
| Jun 30, 2023 | 12.47 Mn |
| Mar 31, 2023 | 12.79 Mn |
| Dec 31, 2022 | 11.59 Mn |
| Sep 30, 2022 | 10.99 Mn |
| Jun 30, 2022 | 7.00 Mn |
| Mar 31, 2022 | 195,000.00 |
| Dec 31, 2021 | 199,000.00 |
| Sep 30, 2021 | 192,000.00 |